JP2024525578A5 - - Google Patents

Info

Publication number
JP2024525578A5
JP2024525578A5 JP2024500303A JP2024500303A JP2024525578A5 JP 2024525578 A5 JP2024525578 A5 JP 2024525578A5 JP 2024500303 A JP2024500303 A JP 2024500303A JP 2024500303 A JP2024500303 A JP 2024500303A JP 2024525578 A5 JP2024525578 A5 JP 2024525578A5
Authority
JP
Japan
Prior art keywords
seq
nucleoside
composition
modified rna
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525578A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073463 external-priority patent/WO2023283576A1/en
Publication of JP2024525578A publication Critical patent/JP2024525578A/ja
Publication of JP2024525578A5 publication Critical patent/JP2024525578A5/ja
Pending legal-status Critical Current

Links

JP2024500303A 2021-07-06 2022-07-06 C型肝炎ウイルスのためのP7含有ヌクレオシド-改変されたmRNA-脂質ナノ粒子系統ワクチン Pending JP2024525578A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218685P 2021-07-06 2021-07-06
US63/218,685 2021-07-06
PCT/US2022/073463 WO2023283576A1 (en) 2021-07-06 2022-07-06 P7 containing nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus

Publications (2)

Publication Number Publication Date
JP2024525578A JP2024525578A (ja) 2024-07-12
JP2024525578A5 true JP2024525578A5 (https=) 2025-07-14

Family

ID=84802063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500303A Pending JP2024525578A (ja) 2021-07-06 2022-07-06 C型肝炎ウイルスのためのP7含有ヌクレオシド-改変されたmRNA-脂質ナノ粒子系統ワクチン

Country Status (7)

Country Link
US (1) US20240358821A1 (https=)
EP (1) EP4366770A4 (https=)
JP (1) JP2024525578A (https=)
CN (1) CN117915946A (https=)
AU (1) AU2022307932A1 (https=)
CA (1) CA3224943A1 (https=)
WO (1) WO2023283576A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005524A1 (en) * 2002-07-02 2004-01-15 Merck & Co., Inc. Hepatitis c virus particle formation
EP1537206B1 (en) * 2002-09-13 2009-05-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins
US8178086B2 (en) * 2006-01-04 2012-05-15 Novartis Vaccines And Diagnostics, Inc. Activation of HCV specific T cells
AU2016253972B2 (en) * 2015-04-27 2020-01-02 Acuitas Therapeutics Inc. Nucleoside-modified RNA for inducing an adaptive immune response
EP3445396A4 (en) * 2016-04-22 2020-03-11 Integrated Research Associates, LLC IMPROVED PROCESS FOR PRODUCING VIRUS-LIKE PARTICLES
CN110402145A (zh) * 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法
US11596679B2 (en) * 2017-04-27 2023-03-07 Vanderbilt University Hepatitis C virus gene sequences and methods of use therefor
WO2019210144A1 (en) * 2018-04-27 2019-10-31 Vanderbilt University Broadly neutralizing antibodies against hepatitis c virus

Similar Documents

Publication Publication Date Title
JP2021182922A5 (https=)
EP3851120A1 (en) Immunogen for broad-spectrum influenza vaccine and application thereof
CN116082521B (zh) 痘病毒多抗原嵌合疫苗及其用途
JP2023513720A5 (https=)
JP2023514594A5 (https=)
JP2004501646A5 (https=)
CN116218879A (zh) 一种单价广谱的正痘病毒属mRNA疫苗及其应用
JP2024540061A5 (https=)
JP2023522154A5 (https=)
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
US20250339511A1 (en) Nucleic acid vaccine against monkeypox virus and use thereof
WO2022071513A1 (ja) SARS-CoV-2に対する改良型DNAワクチン
JP2023536570A5 (https=)
WO2023051701A1 (zh) 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
JP2024521098A5 (https=)
CN116171168A (zh) 通过靶向抗原表达增强免疫应答
JP2022078067A5 (https=)
WO2024055272A1 (zh) 能高效表达目的基因的mRNA载体系统、其构建及应用
JP2024525578A5 (https=)
JP2024523329A5 (https=)
CN116904489B (zh) 一种鸭坦布苏病毒核酸疫苗及应用
KR20250067065A (ko) 재조합 sfts 바이러스 기반 2가 백신 조성물
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
JP2024540976A5 (https=)
JP2023526045A5 (https=)